NCT06622590View on ClinicalTrials.gov

Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

October 13, 2024

Primary Completion Date

January 9, 2025

Study Completion Date

July 31, 2025

Conditions
Influenza, HumanInfluenza aInfluenza Type BInfluenza Viral Infections
Interventions
BIOLOGICAL

QIV

Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose

BIOLOGICAL

QIV control

Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose

Trial Locations (1)

Unknown

Binyang Center for Disease Control and Prevention, Nanning

All Listed Sponsors
collaborator

Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control

OTHER_GOV

lead

Institute of Medical Biology, Chinese Academy of Medical Sciences

OTHER

NCT06622590 - Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine | Biotech Hunter | Biotech Hunter